Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04647214 · ClinicalTrials.gov registry record
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
A clinical trial of Ocular Hypertension and Open Angle Glaucoma, sponsored by Allergan.
- Completed
- Registry status
- 220
- Enrollment target
- 20
- Study locations
NCT04647214: Completed study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Allergan.
NCT04647214 is a study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Allergan. The registered enrollment target is 220 participants, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04647214, a study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Primary Outcome
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Conditions Studied
Study Locations (20)
Florida
- Eye Associates of Fort Meyers /ID# 244476 - Fort Myers
- MedEye Associates /ID# 240374 - Miami
- Center for Sight - Sarasota /ID# 244578 - Sarasota
- Newsom Eye & Laser Center /ID# 253287 - Sebring
- Dr. Andrew Gardner Logan, FL /ID# 240361 - Tamarac
- Your Eye Specialists /ID# 253286 - Weston
California
- Angeles Eye Institute /ID# 240368 - Culver City
- Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240364 - La Jolla
- American Institute of Research /ID# 247820 - Los Angeles
- North Bay Eye Associates Inc. /ID# 240362 - Petaluma
- Pacific Eye Associates /ID# 240536 - San Francisco
Colorado
- Colorado Eye Institute /ID# 240798 - Colorado Springs
- ICON Eye Care /ID# 240681 - Grand Junction
Missouri
- Midwest Vision Research Foundation at Pepose Vision Institute /ID# 240537 - Chesterfield
- Wiles Eye Center /ID# 240808 - Kansas City
Georgia
- Georgia Eye Partners /ID# 240061 - Atlanta
Illinois
- Kovach Eye Institute /ID# 244581 - Elmhurst
Kansas
- Stiles Eyecare Excellence /ID# 240376 - Overland Park
Kentucky
- The Eye Care Institute /ID# 240367 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2024-07-12 |
What the finished NCT04647214 record still lists
NCT04647214 is an observational study that tracks outcomes without assigning an intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (20% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT04647214 names 20 study sites across 9 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04647214 about?
NCT04647214 is a clinical study titled "18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)". Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT04647214?
This trial is currently completed. The enrollment target is 220 participants. The study started on 2021-03-03. Estimated completion is 2024-07-12.
What conditions does trial NCT04647214 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
Who is sponsoring clinical trial NCT04647214?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04647214 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04647214's enrollment target sits among peer trials
220 21st of 54 higher than 34 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI